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Abstract. The effect of supplementation with the omega 3 polyunsaturated fatty acid (n-3 PUFA) docosahexaenoic acid (DHA)
on membrane composition and amyloid-β1−42 (Aβ42) secretion was studied in human amyloid-β protein precursor-transfected
Chinese Hamster Ovary (CHO) cells. Twenty-four hour incubation with a range of DHA concentrations resulted in a dose-
dependent increase in membrane DHA and eicosapentaenoic acid content and a decrease in arachidonic acid content. In addition,
DHA supplementation caused a dose-dependent reduction in the secreted Aβ42 levels and resulted in a 4–8 fold decrease in
extracellular prostaglandin E2 (PGE2) levels. Tocopherol, which was added to DHA to prevent oxidation, may have contributed
to the effect of DHA, since it slightly decreased extracellular Aβ42 and PGE2 levels when given alone. The addition of selective
COX-2 inhibitors Celebrex and curcumin to the culture medium resulted in a significant and comparable inhibition of PGE2
release, but did not inhibit Aβ42 secretion, and even significantly increased Aβ42 production in this cell system. Together, the
present data show that, whereas both DHA and COX-2 inhibitors may reduce PGE2 production, only DHA in the presence of
tocopherol significantly reduced Aβ42 production and concurrently changed membrane lipid composition in CHO cells. It is
concluded that in this in vitro setting DHA reduced Aβ42 secretion through membrane-related, but not PGE2-related mechanisms.
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INTRODUCTION
With the aging population, the number of people de-
veloping Alzheimer’s disease (AD) will increase dra-
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E-mail: martijn.dewilde@danone.com.
matically. Epidemiological studies have shown that
the risk of developing AD decreases with increased in-
take of fatty fish [1]. Especially the intake of omega-
3 (n-3) polyunsaturated fatty acids (PUFAs), such as
docosahexaenoic acid (DHA) and eicosapentaenoic
acid (EPA), is associated with this decreased risk. To-
day, dietary intake of n-3 PUFAs in Western countries
is lower than recommended. Especially during the last
century, the intake of omega-6 (n-6) PUFAs has in-
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creased at the cost of n-3 PUFAs resulting in a reduced
n-3/n-6 ratio [2–4]. Since, both n-6 and n-3 PUFAs
compete for the enzyme cyclooxygenase (COX) [5,6],
increased intake of n-6 PUFAs leads to a higher pro-
duction of the n-6 derived pro-inflammatory eicosanoid
prostaglandin E2 (PGE2).
A key factor in the development of AD is the forma-
tion of dense plaques in the patient’s brain. One of the
components of these plaques is amyloid-β (Aβ), the
predominant species being Aβ1−42 (Aβ42), which is
formed by cleavage of the amyloid-β protein precursor
(AβPP) by β- and γ-secretases. Interestingly, several
studies have shown that PGE2 itself or stimulation of
COX-2 activity leading to increased PGE2 production,
can promote Aβ formation, likely through stimulation
of γ-secretase activity [7,8]. Reducing the formation
of PGE2 by increasing n-3 PUFAs [9], might therefore,
offer an effective method to diminish the secretion of
Aβ.
Studies in transgenic models for AD suggest that Aβ
burden, inflammation, and behavioral deficits can be
attenuated by pharmacological COX inhibition by non-
steroidal anti-inflammatory drugs (NSAIDs) [10–12].
Increased COX-2 activity in AβPPswe-PS1dE9 mice
by transfection with human COX, however, resulted in
cognitive deficits that could be reversed by pharmaco-
logical COX-2 inhibition, but did not increase Aβ bur-
den [13]. The absence of an effect of COX overex-
pression on Aβ production in vivo may depend on the
age of the animals, since it confirmed a previous study
where effects were found in 24 months (mo) old, but
not in 8–12 mo old double transgenic mice [7] model-
ing an earlier stage of AD. These results may suggest
that existing Aβ deposits may be necessary to elicit
COX-2 mediated potentiation of Aβ deposition. This
is supported by the fact that elevated levels of PGE2
and overexpression of COX-2 have been observed in
the brains of AD patients [14–16], and that the extent
of COX-2 expression correlates with the amount of Aβ
and the degree of progression of AD pathogenesis [17].
The present study aimed to test whether in vitro
supplementation with the n-3 PUFA DHA can lower
Aβ42 secretion by reducing PGE2 production. To this
end, human AβPP transfected Chinese Hamster Ovary
(CHO) cells were supplemented with a range of DHA
concentrations, and both amyloidogenic Aβ42 secre-
tion and PGE2 production were measured. The rela-
tionship between PGE2 production and Aβ secretion
was further investigated by applying selective COX-1
& -2 inhibitors to the cells. Finally, since DHA sup-
plementation is known to change membrane composi-
tion [18,19], and AβPP processing is hypothesized to
be influenced by membrane composition [20,21], we
also measured membrane phospholipids and membrane
fatty acids in the present study.
MATERIALS AND METHODS
Cell culture
CHO-7PA2 cells from a Chinese Hamster Ovary cell
line, stably transfected with a cDNA for the 751 form
of AβPP bearing the V717F familial AD mutation,
and driven by a CMV promoter, were kindly provided
by Dr. Selkoe and described in detail elsewhere [22].
Cells were cultured in DMEM/F-12 containing 10%
FCS, 2 mM glutamine and 100 µg/ml geneticin (G418)
(all components were purchased from Invitrogen Life
Technologies, Merelbeke, Belgium). The addition of
10% FCS to the culture medium was necessary to al-
low DHA supplementation and therefore used in all
experimental conditions.
DHA supplementation
For measurement of Aβ42, PGE2 and fatty acid anal-
yses, 6-well plates were seeded with approximately
200,000 cells per well and incubated at 37◦C. After 24 h
the culture medium was replaced by fresh medium sup-
plemented with a range of DHA (> 98% pure, Sigma-
Aldrich Chemie, Zwijndrecht, The Netherlands) con-
centrations (40, 50, 60, 70, 80, 90, or 100 µM). DHA
was added to 10% FCS after which glutamine and ge-
neticin were added (see above). α-Tocopherol (20µM)
(> 96% pure, Sigma) was added standard to the culture
medium as a protective agent [23]. Twenty-four hours
later cells were harvested, Aβ42 content was measured
(see Aβ42 assay below), and the fatty acid composi-
tion of the cell membranes was analyzed. Cell via-
bility after DHA supplementation was measured by a
water soluble tetrazolium (WST) (Roche Diagnostics,
Almere, The Netherlands) and a lactate dehydrogenase
assay (LDH) (Roche) carried out according to the man-
ufacturer’s instructions.
For phospholipid analyses, cells were cultured in
T175 flasks (Becton Dickinson BV, Alphen aan de
Rijn, The Netherlands) and 24 h later culture medium
was refreshed and supplemented with 100µM DHA for
another 24 h. Following treatment with trypsin (trypsin
EDTA in HBSS, Invitrogen) the number of cells was
determined using a Coulter Counter. The cell suspen-
sion was centrifuged at 1000 rpm for 5 min, the su-
pernatant removed and cell pellets stored at−20◦C for
fatty acid analysis.
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CMV-luciferase transfection
To control for possible effects of DHA supplemen-
tation on promoter activity, additional 24-well plates
were cultured with CHO cells. After 24 h the cells
were transfected with CMV-luciferase using FuGENE
6 Transfection Reagent (Roche) and incubated with
DHA (40, 60, 80, and 100 µM) for another 24 h. Lu-
ciferase signal was measured using the Dual-Luciferase
Reporter Assay System (Promega Benelux BV, Leiden,
The Netherlands). Reduced luciferase activity would
be indicative for a reduction of promoter activity as a
result of DHA supplementation. Reductions in pro-
moter activity would result in lower levels of AβPP and
therefore lower levels of Aβ42.
Aβ42 assay
Medium samples (900 µl) taken from supplement-
ed 6-well plates, were loaded on a PD10 desalt-
ing column (Amersham Biosciences, Roosendaal, The
Netherlands). Samples were concentrated by using a
speedvac and dissolved again in 100 µl lysis buffer
(62.5 mM Tris-HCl, pH 6.8; 4% SDS and 20% glyc-
erol, according to Prof. Wurtman, Boston, USA). Aβ42
analysis was performed using the Signal Select Human
Aβ42 ELISA assay kit (Biosource BV, Etten-Leur, The
Netherlands). The assay was carried out according to
the manufacturer’s protocol. BSA solution (Omnilabo,
Breda, The Netherlands) was used to create a standard
curve with a range of 1.5–0.025 mg/ml. Standards
and 10-times diluted samples (25 µl) were loaded on
a 96-well plate (Becton Dickinson BV) and 200 µl of
working reagent was added (1 part BCA Protein As-
say Reagent B and 50 parts BCA Protein Assay, both
Perbio). After 30 min incubation at 37◦C absorbance
at 550 nm was measured. Sensitivity of the kit lies
between 0 and 1000 pg/mL Aβ42 and samples were
diluted accordingly to fall within this range. The Aβ42
results were corrected for cell numbers and expressed
per 1 × 106 cells.
PGE2 assay
PGE2 production was determined by Prostaglandin
E2 EIA Kit- Monoclonal (Campro Scientific, Veenen-
daal, The Netherlands) in medium taken from the 6-
well plate. Samples were diluted with EIA buffer (1:3)
and processed according to the manufacturer’s proto-
col. The amount of PGE2 (in ng) was corrected for cell
numbers. Sensitivity of the kit lies between 2 and 2000
pg/mL PGE2 and samples were diluted accordingly to
fall within this range.
COX inhibition
One selective COX-1 inhibitor, SC-560 (VWR In-
ternational, Roden, The Netherlands), and two se-
lective COX-2 inhibitors, Celebrex (Pharmacia B.V.,
Woerden, The Netherlands) and curcumin (Sigma-
Aldrich Chemie, Zwijndrecht, The Netherlands), were
used to inhibit the production of PGE2. CHO cells
were cultured on a 6-well plate and incubated with one
of the COX-inhibitors for 24 h. SC-560 was added in
a concentration of 3.75–60.0 nM, Celebrex in a con-
centration range of 0.037–6.0 µM, and curcumin in
0.0675–27.0 µM. The effects on Aβ42 secretion and
PGE2 production were determined after 24 h incu-
bation (procedures as described above). In addition,
PGE2 levels were measured after 24 h incubation with
synthetic PGE2 (0.1, 0.5, 1.5, 3 and 6 pg synthet-
ic PGE2/ml (5Z, 11a, 13E, 15S)-11, 15Dihydroxy-9-
oxoprosta-5,13-dienoic acid, Sigma) in the presence or
absence of 80 µM DHA (analysis as described above).
Fatty acid analysis
Cell pellets from DHA and COX-inhibitor sup-
plemented cells were dissolved in 250 µl dem-
ineralized water. As an internal standard 500 µl
1,2-dinonadecanoyl-sn-glycero-3-phosphocholine was
used. Total lipid was extracted from the cells by
methanol and chloroform. Subsequently, samples were
centrifuged at 3000 rpm for 10 min and the lower phase
(chloroform and lipids) was removed. Chloroform was
added to the upper phase, samples were centrifuged
again at 3000 rpm for 10 min and the lower phase was
combined with the first one. The chloroform fractions
were dried in a speedvac and the lipid extracts were dis-
solved in 125 µl chloroform. The phospholipids were
separated from total lipid by SPE columns (Bond Elut
NH2, Varian).
To determine the fatty acid content of the phospho-
lipids, the phospholipids extract was methylated by
adding 0.5 ml 10% BF3. The samples were heated at
100◦C for 60 min, and 2 ml hexane and 1 ml sodium hy-
droxide were added. After vortexing and centrifuging
the samples for 5 min at 3000 rpm, the lower phase was
vortexed and centrifuged with 2 ml hexane for 5 min at
300 rpm. Top phases of both steps were combined and
hexane was evaporated from the samples by means of
a speedvac. The fatty acids were dissolved in 125 µl
iso-octane and analyzed on a GC-FID with a CP-SIL88
column (50 m × 0.25 mm id. 0.22 µm film thickness).
Data are expressed as amount of fatty acid per 1× 106
cells.
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Phospholipids analysis
The cell pellets were dissolved in 250 µl deminer-
alised water and lipids were extracted using methanol-
chloroform. Concentrated lipid extracts (speedvac)
were used for the separation and quantification of the
phospholipids by HPLC-LSD with a LiChrospher Diol-
100 column (250 × 4.6 mm, 5 µm, Merck). The
separation of the phospholipids from the CHO cells
was accomplished by a gradient of two mobile phas-
es: 1) hexane: iso-propanole: acetic acid, 2) iso-
propanole: water: acetic acid. Both mobile phases
were supplied with 0.08% of triethylamine. The gradi-
ent changed linearly from 95:5 to 10:90 within 28 min
and 1 min after reaching the final ratio, the gradient was
changed back to the original composition at a flow rate
of 1 ml/min. Peaks were identified by comparison with
phospholipid standards (3-sn-phosphatidic acid sodi-
um salt, 3-sn-phosphatidyl-l-serine from bovine brain,
3-sn-phosphatidylethanolamine from bovine brain, L-
α-phosphatidylcholine 99% from bovine brain, L-α-
phosphatidylinositol ammonium salt from bovine liver
and sphingomyelin from bovine brain obtained from
Sigma. Data are expressed as amount of phospholipid
class per 1 × 106 cells.
Statistical analyses
All data are expressed as means with standard de-
viations. Data of supplemented cells were compared
to cells incubated in control medium. Data were ana-
lyzed using ANOVA in SPSS 15.0 (SPSS Inc., Chica-
go, IL). All p < 0.05 were considered significant. If
a significant main effect was found with ANOVA, da-
ta were subjected to post-hoc testing with Bonferoni
correction. Visual inspection of the effect of DHA on
Aβ42 secretion and the n3/n6 ratio indicated that the
two effects were related. The averages of both Aβ42
and n3/n6 ratio were plotted for an exploratory corre-
lational analysis and linear regression was performed.
RESULTS
General
Incubation of the CHO cells with the different sup-
plementation conditions did not affect phenotypic ap-
pearance of the cells excepting cells incubated with
the highest dose of DHA, which showed phenotypic
signs of reduced viability. Incubation of CHO cells
Fig. 1. Dose-dependent decrease in extracellular Aβ42 levels after
24 h incubation with DHA (F = 4.2, p < 0.018). Data are plotted as
ng Aβ42 per 1 x 106 cells. Asterisk indicates a significant difference
compared to C in post-hoc analyses.
with different doses of DHA required the addition ofα-
tocopherol to prevent cell death. To control for possible
effects ofα-tocopherol on the different read-out param-
eters, a separate experiment was carried out wherein
cells were cultured in plain medium or medium with
added α-tocopherol. The results showed that addition
of 20 µM α-tocopherol had no effect on PGE2 produc-
tion, membrane composition, and on CMV-promoter
activity (data not shown). Aβ42 secretion was slightly,
but not significantly, decreased by α-tocopherol.
Aβ42 secretion
Incubation of CHO-7PA2 cells with DHA for 24 h
resulted in a dose-dependent decrease in Aβ42 secretion
in the medium (Fig. 1) (F = 4.2, p < 0.018). This
decrease reached significance at a dosage of 60 µM
DHA and higher compared to control, with 100 µM
being most effective in lowering Aβ42 secretion. These
results were confirmed in three separate experiments.
The viability of the cells was checked using a WST
and LDH test. Cells incubated with doses up to 80 µM
DHA showed no changes in viability. Incubation with
100 µM DHA resulted in an 11% decrease of WST
levels compared to control and doses up to 80µM. LDH
levels increased by 18% compared to control and doses
up to 80 µM. Therefore, the highest dose was not used
for further supplementation experiments.
PGE2 production
Cells supplemented with DHA displayed a 4- to 8-
fold decrease in PGE2 production (F = 8.4, p = 0.001)
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Fig. 2. Extracellular PGE2 levels after 24 h incubation with DHA.
PGE2 concentrations decreased with increasing DHA concentrations
(F = 12.9 p < 0.001). Data are plotted as ng PGE2 per 1 × 106
cells. Significant differences compared to C are indicated with *.
(Fig. 2). The effect of DHA supplementation on PGE2
production was already significant at the lowest dose of
DHA used (40µM) and increased at higher doses. Sen-
sitivity of the kit lies between 2 and 2000 pg/mL PGE2
and samples were diluted accordingly to fall within this
range.
COX inhibition
Supplying the cells with the COX inhibitors SC-560,
Celebrex, or curcumin resulted in a reduction of PGE2
in the culture medium (Fig. 3). SC-560 and Celebrex
both completely blocked PGE2 production, while Cur-
cumin dose-dependently decreased PGE2 production
(F = 63.5, p < 0.001; F = 153.5, p < 0.001; F = 82.0,
p < 0.001 respectively). Figure 4 depicts the effects
of COX-inhibitors on Aβ42 levels. Incubation with
COX-inhibitors resulted in a dose-dependent increase
in Aβ42 levels (F = 5.8, p = 0.001). Post-hoc analyses
revealed that this effect was significant for the COX-2
inhibitors Celebrex and Curcumin (F = 8.8, p < 0.001)
but not for COX-1 inhibition with SC-560 (F = 1.1,
p = 0.46).
Incubation of the cells with synthetic PGE2 for 24
h increased the level of PGE2 dose-dependently in the
cell medium to respectively 2 and 2.3 fold compared to
control at 3 and 6 pg PGE2/ml. In the presence of 80
µM DHA, PGE2 levels were significantly lower at all
concentrations PGE2 added, with a 6 fold reduction in
the lower ranges and a 2.3 fold reduction in the higher
ranges of PGE2 added (Fig. 5). Cells incubated with
DHA and the highest dose of synthetic PGE2 showed
comparable absolute PGE2 levels compared to cells
incubated with the lowest dose of synthetic PGE2 in the
Fig. 3. Extracellular PGE2 production after 48 h incubation with
a selective COX-1 inhibitor (SC-560) or two selective COX-2 in-
hibitors (Celebrex or curcumin). All three inhibitors show a pro-
found inhibition of PGE2 production (F = 63.5, p < 0.001; F =
153.5, p < 0.001; F = 82.0, p < 0.001 respectively). Curcumin
requires higher dosages to inhibit PGE2 production, whereas SC-560
and Celebrex show considerable inhibition at the lowest dose used.
Data are shown as amount of PGE2 per 1 x 106 cells. Significant
differences compared to control dose are indicated with *.
Fig. 4. Secretion of Aβ42 after 48 h incubation with a selective
COX-1 inhibitor (SC-560) or two selective COX-2 inhibitors (Cele-
brex or curcumin). ANOVA revealed a dose-depent increase in Aβ42
levels (F = 5.8, p < 0.001) after incubation with COX-inhibitors.
Post-hoc analyses showed that this effect was specific for COX-2
inhibitors (Celebrex and Curcumin) and not for COX-1 inhibitor
SC-560 (respectively: F = 8.8, p < 0.001; F = 1.1, p = 0.46). Data
are plotted as concentration Aβ42 per 1× 106 cells. ns indicates no
significant.
absence of DHA. The membrane n3/n6 ratio was not
affected by PGE2 incubation and equaled 0.95 ± 0.03
(mean ± S.E.M.) as typically seen in control cells.
Membrane composition
Table 1 presents phospholipid levels of cells incu-
bated for 24 or 48 h with control or DHA supple-
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Table 1
Membrane phospholipid levels in cells incubated for 24 and 48 h
Control 24 h DHA 24 h Control 48 h DHA 48 h
PE 1581.8 ± 22.23 1606.7 ± 26.41 1531.7 ± 0.11 1533.0 ± 1.35
PC 2271.5 ± 62.60 2258.4 ± 59.53 2044.3 ± 1.17 2028.0 ± 5.68
PS 1043.9 ± 7.63 1041.2 ± 5.32 1021.3 ± 0.05 1020.3 ± 0.30
PI 948.2 ± 0.49 948.3 ± 0.62 947.4 ± 0.00 947.4 ± 0.08
Phospholipid levels are expressed in ng per 1 × 106 cells. PE: phosphatidy-
lethanolamine, PC: phosphatidylcholine, PS: phosphatidylserine, PI: phos-
phatidylinositol.
Fig. 5. Concentrations of PGE2 in the medium after addition of
increasing doses of PGE2alone or in combination with 80 µM DHA
for 24 h. Univariate analysis of variance indicated main effects of
the factor Dose (having 6 levels) [F = 16.7, p < 0.001] and the
factor DHA (having 2 levels) [F = 60.4, p < 0.001]. No significant
interaction between Dose and DHA was found (p = 0.31). Post-hoc
comparisons of Doses indicated that: 0 = 0.1 = 0.5 = 1.5 < 3 < 6
(all p < 0.015). # indicates the significant difference between cells
incubated without or with DHA. Significant differences compared to
the respective control dose are indicated with *.
mented medium. The phospholipid composition of the
membranes after 24 h incubation was comparable be-
tween DHA and control incubated cells (F = 0.042,
p = 0.838). To exclude the possibility that time had
not been sufficient to affect phospholipid incorporation,
cells were also incubated for 48 h. Again no effect of
supplementation with DHA on the composition of the
membranes phospholipids was found.
Membrane fatty acid composition showed an in-
crease in n-3 PUFAs after 24 h incubation with DHA,
in particular the amounts of DHA and EPA were in-
creased (F = 86.3, p < 0.001 and F = 45.5, p < 0.001
respectively) (Fig. 6). Also, a reduction was found in
the total amount of arachidonic acid (AA) as a result
of DHA supplementation (F = 5.7, p < 0.03) (Fig. 6).
Together, these effects resulted in a dose-dependent in-
crease in the n-3/n-6 ratio from 0.9 in control cells to
3.9–5.3 (40 µM and 80 µM respectively) in 24 h DHA
supplemented cells (F = 211.5, p < 0.001) (Fig. 6).
Figure 7 depicts the explorative correlation between
the percentage decrease in Aβ42 levels compared with
control and the percentage increase in the n3/n6 ra-
tio. Regression analysis revealed an rs = 0.936 with a
significance of p = 0.032.
Promoter activity and cell proliferation
The additional transfection of the CHO-7PA2 cells
with a CMV-luciferase construct and incubation with
DHA for 24 h resulted in an increased luciferase ac-
tivity compared to cells incubated without DHA (F =
16.4, p < 0.001) (Fig. 8). The effect of DHA supple-
mentation reached significance at a dose of 60 µM.
To control for differences in cell proliferation, cell
counts for the different DHA doses were performed.
No effect of DHA supplementation was found on cell
numbers (data not shown).
DISCUSSION
In humans, consumption of n-3 PUFAs is found to
be inversely related to the risk for developing demen-
tia and, in particular, AD [24,25]. Since one of the
hallmarks of AD is the accumulation over time of Aβ
plaques, in which Aβ42 is the predominant species, this
study investigated the direct effects of the n-3 PUFA
DHA on the secretion of Aβ42 in a robust in vitro sys-
tem. The present study clearly shows that DHA sup-
plementation for only 24 h results in a significant dose-
dependent reduction of Aβ42 in human AβPP trans-
fected CHO-7PA2 cells in vitro. Providing these cells
with DHA also resulted in a drastic increase in plas-
ma membrane DHA and EPA content and a smaller
but significant reduction in AA content which was par-
alleled by diminished PGE2 levels. Incubation with
COX-inhibitors also resulted in very low PGE2 levels,
although COX-inhibitors did not reduce the rate of Aβ
secretion. In fact, incubation with specific COX-2 in-
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Fig. 6. Fatty acid composition of CHO cells after 24 h incubation
with DHA up to 80 µM. Supplementing the cells with DHA resulted
in increased levels of DHA and EPA by approximately 500% and
decreased levels of AA by more than 30% in the membranes (F =
42.3, p < 0.001; F = 20.4, p < 0.003; F = 7.5, p < 0.03, respective-
ly). DHA in addition increased the total amount of n-3 PUFAs and
reduced total amount of n-6 PUFAs resulting in a dose-dependent
increase in the n-3/n-6 ratio (F = 145.2, p < 0.001). Fatty acid data
are expressed as the amount in mg per 1 x 106 cells. The ratio is
calculated as: amount n-3 PUFAs/ amount n-6 PUFAs. Significant
differences compared to C are indicated with *.
hibitors induced an increase in Aβ levels. DHA sup-
plementation did not influence cell proliferation and
cell viability and survival were not affected with con-
centrations of DHA lower than 100 µM. The reduction
in Aβ42 was not the result of lower levels of AβPP as
Fig. 7. Explorative correlation between relative Aβ42 levels and the
percentage increase in membrane n3/n6 PUFA ratio. Plotted are the
relative Aβ42 levels compared to control as a function of the relative
increase in the n3/n6 PUFA ratio. The horizontal and vertical error
bars represent the standard errors of the n3/n6 ratio and the standard
errors of Aβ42, respectively. A regression line including the 95%
confidence interval was plotted (rs = 0.936; p = 0.032). Increasing
membrane n3/n6 PUFA ratios were associated with reduced Aβ42
secretion. The listed concentrations represent the levels of DHA
supplementation of the data points.
Fig. 8. Luciferase activity of CHO cells incubated with several DHA
concentrations. DHA supplementation created a dose-dependent
increase in luciferase activity compared to C (F = 15.0, p < 0.001).
Data are plotted as a relative score compared to C.
a consequence of reduced promoter activity. Rather,
DHA slightly increased promoter activity. The pres-
ence of 10% FCS may have contributed in the lower-
ing of Aβ42. Since FCS was present under all testing
conditions including the control situation it is unlikely
to that FCS has caused the Aβ42 reduction. However,
a synergistic effect cannot be ruled out.
The effect of DHA was evaluated in the presence of
tocopherol. It is known that AD patients, as well as
individuals suffering from mild cognitive impairment,
show a reduction in plasma antioxidant levels [26–30].
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Despite the fact that some studies showed no protec-
tive effect of antioxidants [31,32], others demonstrat-
ed a reduced risk for developing AD [33–35] in cross-
sectional and prospective epidemiological studies. Fur-
thermore, transgenic animals with the AβPPSwe muta-
tion showed reduced oxidative damage and Aβ pathol-
ogy when provided with antioxidants [36,37]. The ex-
act mechanism, however, through which antioxidants
exert their beneficial effects is not clear [38]. Inhibi-
tion of key events in inflammatory processes [39] and
influencing the phosphorylation state of protein kinase
C, a key player in cytokine signaling [40], are suggest-
ed as routes of action in addition to the direct antioxi-
dant properties [41,42]. Since the current experimental
set-up required the addition of α-tocopherol to prevent
oxidation of DHA, it is plausible that the positive re-
sults obtained on Aβ secretion are partly due to the
combination with antioxidant effects. Indeed, already
a small decrease in Aβ secretion, although not signifi-
cant, was observed in cells supplemented with antiox-
idants alone. Therefore, it should be kept in mind that
the obtained results with DHA are on a background of
antioxidants and that a possible interaction cannot be
ruled out. As recently suggested [43], the antioxidant
basis provided by the tocopherol could have contributed
to the magnitude of the effects on amyloidogenic Aβ42
production observed following DHA supplementation.
Given the several-fold stronger dose-dependent reduc-
tion in Aβ by DHA supplementation, the contribution
of α-tocopherol is likely to be small.
In our study, DHA supplementation for 24 h resulted
in a marked reduction in PGE2 production. Already
at a concentration of 40 µM a reduction of 60% was
seen, and higher DHA concentrations were even more
effective in reducing PGE2. The higher doses of DHA
also induced a significant decrease in AA content of
the membrane. Since, AA acts as the progenitor of
PGE2 [6,44] it seems likely that the decrease in AA
levels in the plasma membrane, at least in part, may
account for the reduced levels of PGE2. However, such
a dramatic suppression of PGE2 formation as a result
from a modest reduction in AA content is not supported
by evidence from literature. An alternative explana-
tion for this reduction can be found in the competition
between AA and EPA for the COX-pathway to form
prostaglandins [44–46]. Indeed, the DHA supplemen-
tation regime not only affected DHA and AA levels but
also increased EPA content of the membrane to 500%
of control levels, which is approximately half of the AA
membrane content. Supplementing EPA to carcinoma
cell lines indeed reduced PGE2 production in a dose-
dependent manner while supplementation of compara-
ble doses of AA induced increases in PGE2 levels [47,
48]. Thus, supplementing CHO cells with DHA shifts
the balance between AA en EPA in favor of the latter,
likely competitively inhibiting the metabolism of AA
to PGE2 by COX.
The possible relevance of inflammatory factors in
AD is indicated by the elevated levels of COX [49] and
PGE2 [14] observed in AD patients. In a series of el-
egant experiments, Qin et al. [8] showed that Aβ pro-
duction was increased in transfected CHO-AβPPSwe
and H4-AβPP751 cells with human COXs compared to
non-transfected cells. However, in the current study,
the suppression of COX activity by specific COX-1 and
COX-2 inhibitors was not paralleled by a reduction of
Aβ42 formation, despite a marked decrease in PGE2
release. In fact, supplying the cells with the COX-2
inhibitors Celebrex and curcumin promoted Aβ42 se-
cretion. Thus, the effects of DHA on Aβ are not de-
pendent on the reduction in PGE2 and seem to be inde-
pendent of anti-inflammatory properties of DHA. Inter-
estingly, Hoozemans and co-workers showed that ad-
dition of AA to the medium, but not of Aβ peptides,
increased the release of PGE2 from human microglia
and white matter brain tissue independent of COX mR-
NA transcription [50]. Although, prostaglandins are
a contributor to inflammation they are not the sole
source of inflammation. It has been shown that AβPP
transfection produced stress in cells, not only direct-
ly by Aβ production, but also by other metabolites of
AβPP such as N-AβPP [51]. Consequently, transfect-
ed cells can have activated inflammatory signaling such
as NFκB [52], which in turn, could increase COX ex-
pression (thus inhibiting COX would not alter Aβ lev-
els). This would suggest that inflammatory processes
other than prostaglandins may be contributing to Aβ
accumulation.
The molecular mechanisms of action of the n-3
PUFA DHA leading to altered AβPP production or pro-
cessing and Aβ generation have been subject of sever-
al studies [53–56]. These studies show inhibitory ef-
fects of DHA on the endogenous or transgenic induced
Aβ production in the course of several days [54,56] or
weeks [53]. The alterations in membrane DHA content
were largely comparable to those observed after 24 h
supplementation in our cell cultures. Supplementation
of DHA in our cell system not only increased DHA
and EPA content of the membranes but also decreased
AA content. Inhibition of AA metabolism has been
shown to alter the secretion of the N-terminal frag-
ment of AβPP in vitro [57]. The stimulatory effect of
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AA on AβPP release in another in vitro study, how-
ever, was comparable to activation of PLA2, the en-
zyme that releases AA from cellular stores [58]. This
pathway has been implicated in the observed effects of
DHA on AβPP processing by stimulating the genera-
tion of neuroprotectin D1 from DHA, thereby inducing
an anti-apoptotic, neuroprotective gene-expression pro-
gram that regulates the secretion of Aβ peptides [53].
It has also been suggested that DHA can inhibit the
secretion and oligomerization of Aβ directly irrespec-
tive of the level of Aβ production [59]. DHA sup-
plementation has also been associated with a reduction
in steady-state levels of presenilin 1 thereby directly
limiting γ-secretase activity resulting in decreased Aβ
production [55]. Finally, the current study did not test
and therefore cannot rule out that DHA may have de-
creased Aβ levels by increasing the levels of sorting and
scavenging proteins [56,60–62] or by altering AβPP
processing through changed membrane properties as a
result of an increased n3/n6 PUFA ratio [56,61] and/or
decreased membrane cholesterol content [63,64].
Our current data showing a strong correlation be-
tween Aβ42 and PUFA ratio, best support the latter
pathway and suggests that increasing the n3/n6 ratio
decreases Aβ formation and confirms in vivo studies
with AβPP/PS1 mice showing increased Aβ levels with
increased n6/n3 ratios [54]. Future studies should fo-
cus on the exact mechanism behind the Aβ42 reduction,
as well as on effects of combinations of nutrients like
nucleotides, B-vitamins or phospholipids, which may
enhance the Aβ lowering effect of DHA [65].
In summary, DHA supplementation in the presence
of α-tocopherol effectively suppressed Aβ42 secretion
in human AβPP-transfected CHO-7PA2 cells by 60%.
The DHA supplementation resulted in a 500% increase
in plasma membrane DHA and EPA content, and a de-
crease by 30% in AA levels. In addition, DHA sup-
plementation resulted in an 8-fold decrease in PGE2
production. Cell proliferation and promoter activity
were eliminated to be the origin of the observed DHA
effects. Moreover, incubation with selective COX in-
hibitors, that reduced PGE2 production effectively, did
not affect Aβ42 secretion. Thus, it is not likely that
incubation with DHA reduces Aβ42 secretion through
PGE2 related pathways, but rather is a more direct con-
sequence of the increased membrane content of DHA
and the altered membrane ratio in n3/n6 PUFAs and/or
intracellular events that influence AβPP processing and
cleavage directly.
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